Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>In Vivo</i>
Hong Qin(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Han Sun(City Of Hope National Medical Center), Wesley A. Cheng(City Of Hope National Medical Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Kunhwa Kim(The University of Texas MD Anderson Cancer Center), D. Lynne Smith(City Of Hope National Medical Center), Zhenyuan Dong(Chinese Academy of Sciences), Feng Wen(PLA Navy General Hospital), Soung-chul Cha(The University of Texas MD Anderson Cancer Center), Ippei Sakamaki(University of Toyama), Guo‐Wei Wei(Michigan State University), Laura Bover(The University of Texas MD Anderson Cancer Center)
Cited by 30
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|236